Community-acquired pneumonia: current management

2016-12-16
Mark Woodhead

This lecture was recorded at the 2nd McMaster International Review Course in Internal Medicine in Kraków, Poland. To learn more, visit www.mircim.eu.

See also
  • Treatment of latent TB infection in patients with rheumatoid arthritis The WHO advocates several regimens for the treatment of latent tuberculosis (TB) infection. Are there any new data comparing different treatments that suggest which regimen would be optimal for adults with rheumatoid arthritis (RA) who have been treated for latent TB infection before starting biologic therapy for RA?
  • Bariatric surgery in diabetes and obesity A lecture by Prof. Maria Tiboni, from McMaster University, Canada, delivered at McMaster International Review Course in Internal Medicine in Kraków in May 2016.
  • Emerging approaches to the treatment of type 2 diabetes mellitus A lecture by Prof. Hertzel Gerstein, from McMaster University, Canada, delivered at McMaster International Review Course in Internal Medicine in Kraków in May 2016.
  • Treatment of CAP and resistant pathogens There is a tendency to keep the duration of antibiotic treatment for community-acquired pneumonia as short as possible. Treatment of 5 days is safe and effective but is it associated with an increased risk of selection of resistant pathogens?
  • Noninvasive ventilation in long-term treatment of COPD There are some data that noninvasive ventilation could be useful in long-term treatment of some patients with COPD. Apart from the information from arterial blood gas analysis, which data should we use to decide which stable hypercapnic patients with COPD will benefit most from NIV? Is there a subgroup of patients in whom this treatment should be routinely used?
  • Steroids in pneumonia and ARDS Dr Bram Rochwerg, critical care expert and member of the Society of Critical Care Medicine and European Society of Intensive Care Medicine Corticosteroid Guideline Task Force, explains the rationale and evidence behind using steroids in pneumonia and ARDS.
  • Differences between the virulence of community-acquired and hospital drug-resistant bacterial strains Is the virulence of community-acquired and hospital drug-resistant bacterial strains (eg, methicillin-resistant Staphylococcus aureus) the same? Are drug-resistant strain infections limited to patients with risk factors or can they also affect healthy persons with no risk factors?
  • Outpatients with chronic cough What studies, in addition to chest x-ray and spirometry, should be performed in outpatients presenting with chronic cough? When should such patients be referred to specialist centers?
  • Prevalence of infections caused by atypical pathogens in CAP Physicians treating patients with CAP tend to overestimate or underestimate the prevalence of infections caused by atypical pathogens. Are there any recent data that could be helpful in identifying patients with atypical infection?
  • Common interstitial lung diseases: practical tips for nonspecialists A lecture by Prof. Luca Richeldi, from University of Southampton, UK, delivered at McMaster International Review Course in Internal Medicine in Kraków in May 2016.

We would love to hear from you

Comments, mistakes, suggestions?